Table 1 Baseline patient clinical characteristics
From: Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas
Characteristic | Number of patients ( n=51) |
|---|---|
Age (range) | 63±15 (29–89) |
⩽60 | 18 |
>60 | 33 |
Sex (M/F) | 32/19 |
GCB | 29 (57%) |
Ann Arbor | |
Stage I/II | 15 |
Stage III/IV | 14 |
IPI | |
Low/low-intermediate (⩽2) | 19 |
Intermediate-high/high (>2) | 10 |
Non-GCB | 22 (43%) |
Ann Arbor | |
Stage I/II | 8 |
Stage III/IV | 14 |
IPI | |
Low/low-intermediate (⩽2) | 9 |
Intermediate-high/high (>2) | 13 |
Serum LDH level>1 × normal | 18 (35%) |
Therapy regimen | R-CHOP |
5-Year overall survival | 69% |
